natgillin/translations-raw huggingface dataset:
After it has been dissolved in the supplied water for injections, the product should be clear.
Potem, ko se je zdravilo raztopilo v priloženi vodi za injekcije, mora biti zdravilo bistro.
In rare cases, Nonafact can give rise to a severe allergic reaction (anaphylactic shock).
V redkih primerih lahko Nonafact povzroči hudo alergijsko reakcijo (anafilaktični šok).
If you have previously experienced hypersensitivity in response to the administration of blood or a blood product, Nonafact
Če ste v preteklosti doživeli preobčutljivostne reakcije po dajanju krvi ali krvnih izdelkov, smete
18 should only be administered when absolutely necessary (in life-threatening situations).
17 prejeti Nonafact le, kadar je to nujno potrebno (v življenje ogrožujočih situacijah).
Activity-neutralising antibodies (inhibitors) is a very rare event in previously treated patients receiving factor IX-containing products.
Protitelesa, ki nevtralizirajo aktivnost (inhibitorji), so zelo redek pojav pri predhodno zdravljenih bolnikih, ki prejemajo zdravila, ki vsebujejo faktor IX.
There is a slight risk that higher doses of Nonafact will cause clots to form in blood vessels, resulting in thrombosis.
Obstaja majhno tveganje, da višji odmerki Nonafacta povzročijo tvorbo krvnih strdkov v žilah, kar povzroči trombozo.
This also applies to newborn babies and patients with an increased risk of thrombosis or “ DIC”, disseminated intravascular coagulation, a disease in which the blood coagulation system is disturbed.
To velja tudi za novorojenčke in bolnike s povečanim tveganjem za trombozo ali “ DIK ”, diseminirano intravaskularno koagulacijo, bolezen pri kateri je moteno delovanje sistema strjevanja krvi.
Your doctor will consider whether administration of Nonafact imposes a risk for coagulation complications.
Vaš zdravnik bo presodil, ali dajanje Nonafacta predstavlja tveganje za zaplete pri strjevanju krvi.
These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/ infections.
Ti vključujejo pozorno izbiranje dajalcev krvi in plazme, da bi tako izključili dajalce, ki so morebitni prenašalci okužb, in testiranje vsake donacije in vseh zbirov plazme na viruse in okužbe.
This also applies to any unknown or emerging viruses or other types of infections The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A and parvovirus B19 viruses.
Privzeti ukrepi se smatrajo za učinkovite proti virusom z ovojnico, kakršni so virus človeške imunske pomanjkljivosti (HIV), virus hepatitisa B in virus hepatitisa C, ter proti virusom brez ovojnice, kakršna sta virusa hepatitisa A in parvovirus B19.
Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/ repeatedly receive human plasma-derived coagulation factor IX
Če redno/ ponavljajoče prejemate koagulacijski faktor IX pridobljen iz človeške plazme, vam bo zdravnik priporočil, da razmislite o cepljenju proti hepatitisu A in B.
There is no experience of the treatment of previously untreated patients with Nonafact.
Izkušenj z zdravljenjem z Nonafactom pri bolnikih, ki predhodno še niso bili zdravljeni, ni.
There are no known interactions between Nonafact and other medicinal products.
Ni znanih interakcij med Nonafactom in drugimi zdravili.
Nonafact has no known effects on the ability to drive and to use machines.
Nonafact nima znanih učinkov na sposobnost vožnje in upravljanja s stroji.
Information about some of the ingredients of Nonafact:
Pomembne informacije o nekaterih sestavinah Nonafacta:
19 This medicinal product contains 75mmol/ l sodium chloride per dose.
18 To zdravilo vsebuje 75 mmol/ l natrijevega klorida na odmerek.
HOW TO USE NONAFACT
KAKO UPORABLJATI NONAFACT
Your doctor will decide how much Nonafact you require.
Vaš zdravnik bo odločil, koliko Nonafacta potrebujete.
If you are administered 1 IU per kilogram of body weight, the concentration of factor IX in your blood will increase by 1.1% of normal activity.
Če dobite 1 i. e. na kilogram telesne mase, se bo koncentracija faktorja IX v vaši krvi povišala za 1, 1% normalne aktivnosti.
Your doctor will determine the dose of Nonafact you need and how frequently you should use it depending on the situation.
Vaš zdravnik bo glede na situacijo določil odmerek Nonafacta, ki ga potrebujete, in kako pogosto ga boste uporabljajli.
Degree of bleeding / Type of surgical procedure
Stopnja krvavitve / Vrsta
Bleeding Early signs of bleeding in joints, muscle bleeding or oral bleeding
(%) (i. e. / dl) Krvavitev Zgodnji znaki krvavitve v sklepih, krvavitev v mišico ali krvavitev v ustni votlini
Life threatening bleeding Surgery
Življenjsko nevarna krvavitev Operacija
Minor including tooth extraction Major
Manjša vključno z izruvanjem zoba Večja
Repeat infusion every 8-24 hours until adequate wound healing, then
Ponovite infuzijo vsakih 8 do 24 ur, do zadostnega celjenja rane, zatem
(pre- and
(pred - in
therapy for at least another 7 days.
zdravite vsaj še naslednjih 7 dni.
postoperative)
pooperacijsko)
20 For long-term prevention of bleeding in individuals with severe haemophilia B, doses of 20 IU to 40 IU of factor IX per kilogram body weight should be given at intervals of 3 to 4 days.
19 Za dolgoročno preprečevanje krvavitev pri posameznikih s hudo hemofilijo B je treba dajati odmerke 20 i. e. do 40 i. e. faktorja IX na kilogram telesne mase v intervalih 3 do 4 dni.
If you have the impression that the effect of Nonafact is too strong or too weak, talk to your doctor.
Če menite, da je učinek Nonafacta premočan ali prešibak, se posvetujte s svojim zdravnikom.
The powder dissolves within 5 minutes to produce a clear, colourless to light-yellow solution.
Prašek se v 5. minutah raztopi v bistro, brezbarvno do svetlo rumeno raztopino.
Once dissolved, the product should be used immediately (at least within 3 hours).
Ko je zdravilo enkrat raztopljeno, ga moramo takoj uporabiti (ali najkasneje v 3. urah).
Nonafact should never be mixed with other medicinal products.
Nonafacta ne smemo nikoli mešati z drugimi zdravili.
Nonafact should be injected into a vein (intravenous administration).
Nonafact je treba injicirati v veno (intravensko dajanje).
2 ml per minute).
Raztopljeno zdravilo injicirajte zelo počasi (približno 2 ml na minuto).
If you use more Nonafact than you should:
Če ste uporabili večji odmerek Nonafacta, kot bi smeli:
As with all medicinal products derived from human blood, the use of Nonafact can cause allergic reactions which may include swelling of the larynx, burning and stinging at the infusion site, chills, flushing, hives, itching and rash, headache, tiredness, nausea, restlessness, fast heart beat, chest tightness, tingling, vomiting, wheezing.
Kot pri vseh zdravilih, izdelanih iz človeške krvi, lahko uporaba Nonafacta povzroči alergijske reakcije, ki lahko vključujejo oteklino grla, pekoče bolečine in zbadanje na mestu infundiranja, mrazenje, oblivanja vročine, koprivnico, srbenje in izpuščaj, glavobol, utrujenost, siljenje na bruhanje, nemir, hitro bitje srca, občutek tiščanja v prsnem košu, mravljinčenje, bruhanje, piskajoče in sopihajoče dihanje.
There is a very slight risk that Nonafact will cause clots to form in blood vessels, resulting in thrombosis.
Obstaja zelo majhno tveganje, da bo Nonafact povzročil tvorbo krvnih strdkov v krvnih žilah, kar bi povzročilo trombozo.
The use of Nonafact may also produce an increase in body temperature in rare cases.
Uporaba Nonafacta lahko v redkih primerih povzroči tudi povišanje telesne temperature.
Your body may develop antibodies (inhibitors) against factor IX, which will inactivate Nonafact.
Vaše telo lahko razvije protitelesa (inhibitorje) proti faktorju IX, kar bo onemogočilo delovanje Nonafacta.
HOW TO STORE NONAFACT
SHRANJEVANJE NONAFACTA
Keep the vial in the outer carton in order to protect from light.
Za zagotovitev zaščite pred svetlobo, vialo shranjujte v zunanji ovojnini.
From a microbiological point of view the product, once dissolved, should be used immediately.
Z mikrobiološkega vidika je treba zdravilo, ko ga enkrat raztopimo, nemudoma uporabiti.
Immediately before administration, check that the solution is clear.
Neposredno pred dajanjem preverite, ali je raztopina bistra.
Nonafact 100 IU/ ml human coagulation factor IX
Nonafact 100 i. e. / ml človeški koagulacijski faktor IX
What Nonafact contains
Kaj vsebuje Nonafact
- The active substance is human coagulation factor IX
- zdravilna učinkovina je človeški koagulacijski faktor IX
- The other ingredients are sodium chloride, sucrose, histidine and water for injections.
- pomožne snovi so natrijev klorid, cukroza, histidin in voda za injekcije.
What Nonafact looks like and contents of the pack
Izgled Nonafacta in vsebina pakiranja
Nonafact is presented as a powder and a solvent for solution for injection (vial of 5 ml or 10 ml)
Nonafact je pripravljen v obliki praška in vehikla za raztopino za injiciranje (viala 5 ml ali 10 ml)
Nonafact consists of a carton containing: • A vial of Nonafact containing 500 IU or 1000 IU of factor IX • A vial water for injections containing 5 ml or 10 ml
21 Nonafact sestoji iz ovojnine, ki vsebuje: • Vialo Nonafacta, ki vsebuje 500 i. e. ali 1000 i. e. faktorja IX • Vialo vode za injekcije, ki vsebuje 5 ml ali 10 ml
5 bottles x 90 ml + 1 dosage cup
5 plastenk x 90 ml + 1 merica
bottle (HDPE) bottle (HDPE)
plastenka (HDPE) plastenka (HDPE)
336 soft capsules 84 soft capsules
336 mehkih kapsul 84 mehkih kapsul
4 bottles x 84 capsules 1 bottle x 84 capsules
4 plastenke x 84 kapsul 1 plastenka x 84 kapsul
Norvir is medicine containing the active substance ritonavir.
Norvir je zdravilo, ki vsebuje zdravilno učinkovino ritonavir.
It is available as an oral solution (80 mg/ ml) and as white capsules (100 mg).
Na voljo je v obliki peroralne raztopine (80 mg/ ml) in v obliki belih kapsul (100 mg).
Norvir is an antiviral medicine.
Zdravilo Norvir je protivirusno zdravilo.
It is used in combination with other antiviral medicines to treat adults and children over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Uporablja se v kombinaciji z drugimi protivirusnimi zdravili za zdravljenje odraslih in otrok, starejših od dveh let, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV- 1), ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
It must be taken with food.
Zdravilo je treba zaužiti skupaj s hrano.
Norvir is used in two ways: • It is used as a ‘ pharmacokinetic enhancer ’ (booster) to increase the levels of other antiviral medicines that belong to the same group as Norvir (protease inhibitors), i. e. amprenavir, atazanavir, fosamprenavir, lopinavir, saquinavir, tipranavir and darunavir.
Zdravilo Norvir se uporablja na dva načina: • Kot „ farmakokinetični stopnjevalec “ (spodbujevalec) za povečevanje ravni drugih protivirusnih zdravil, ki spadajo v isto skupino kot zdravilo Norvir (zaviralci proteaz), t. j. amprenavir, atazanavir, fosamprenavir, lopinavir, sakvinavir, tipranavir in darunavir.
For more information, see the Package Leaflet provided with the other medicine. • Norvir can also be used as an antiviral medicine.
Za več informacij glejte navodilo za uporabo, ki je priloženo drugemu zdravilu. • Zdravilo Norvir se lahko uporablja tudi kot protivirusno zdravilo.
The recommended dose for adults is 600 mg twice a day.
Priporočeni odmerek zdravila za odrasle je 600 mg dvakrat na dan.
For children, the recommended dose depends on the body surface area (calculated using the child ’ s height and weight).
Pri otrocih je priporočeni odmerek odvisen od telesne površine (izračunane s pomočjo višine in telesne mase otroka).
Treatment should start with a low dose that is gradually increased over the first 14 days of treatment.
Zdravljenje se začne z nizkim odmerkom, ki ga zdravnik v času prvih 14 dni zdravljenja postopoma povečuje.
The active ingredient in Norvir, ritonavir, is a protease inhibitor.
Zdravilna učinkovina zdravila Norvir je ritonavir, ki spada med zaviralce proteaz.
Ritonavir blocks a viral enzyme called protease, which is involved in the reproduction of HIV.
Ritonavir blokira virusni encim, imenovan proteaza, ki sodeluje pri razmnoževanju virusa HIV.
Ritonavir also blocks the activity of a liver enzyme called CYP3A, which is very important in the breakdown of medicines, including some other protease inhibitors.
Ritonavir zavira tudi aktivnost jetrnega encima z imenom CYP3A, ki je zelo pomemben pri presnovi zdravil, vključno z nekaterimi drugimi inhibitorji proteaz.
By slowing down the rate at which these medicines are broken down, it can increase their levels in the blood and increase their antiviral activity.
Z zaviranjem hitrosti presnove teh zdravil lahko poveča njihove ravni v krvi in s tem tudi njihovo protivirusno aktivnost.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged Zdravilo Norvir v kombinaciji z drugimi protivirusnimi zdravili zniža količino HIV v krvi in jo zadržuje na nizki ravni.
Norvir, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Zdravilo Norvir ne zdravi okužbe s HIV ali AIDS- a, lahko pa podaljša čas do pojava okvar imunskega sistema ter razvoja okužb in bolezni, ki so povezane z AIDS- om.
Norvir has been studied in two main studies, involving 1,446 patients.
Zdravilo Norvir so raziskali v dveh glavnih študijah, ki sta vključevali 1446 bolnikov.
The first study compared 600 mg Norvir taken twice a day with placebo (a dummy treatment) in 1,090 adults, as an add-on to the antiviral medicines the patients were already taking.
V prvi študiji so pri 1090 odraslih primerjali jemanje 600 mg zdravila Norvir dvakrat na dan s placebom (zdravilom brez zdravilne učinkovine), ki so ju dajali kot dodatek ostalim protivirusnim zdravilom, ki so jih bolniki že jemali.
The main measure of effectiveness was the number of patients whose disease worsened or who died.
Glavno merilo učinkovitosti je bilo število bolnikov, katerih bolezen se je poslabšala ali pa so umrli.
The second study compared the same dose of Norvir taken alone, to zidovudine (another antiviral medicine) and to the combination of Norvir and zidovudine, in 356 treatment-naïve adults (who had not taken treatment for HIV infection before).
V drugi študiji so pri 356 bolnikih, ki se pred tem zaradi okužbe s HIV še niso zdravili, primerjali enake odmerke samostojno uporabljanega zdravila Norvir z zidovudinom (drugim protivirusnim zdravilom) in s kombinacijo zdravila Norvir ter zidovudina.
The main measure of effectiveness was the change in the levels of HIV in the blood (viral load) and CD4 T-cell levels in the blood (CD4 cell count).
Glavno merilo učinkovitosti je bila sprememba ravni HIV v krvi (virusno breme) in ravni T- celic CD4 v krvi (število celic CD4).
CD4 T-cells are white blood cells that are important in helping to fight infections, but which are killed by HIV.
T- celice CD4 so bele krvne celice, ki so pomembne za obrambo pred okužbami, a jih virus HIV uničuje.
The use of Norvir as a pharmacokinetic enhancer is supported by clinical studies of the other medicines that it is used with.
Uporabo zdravila Norvir kot farmakokinetičnega stopnjevalca podpirajo klinične študije drugih zdravil, s katerimi se zdravilo Norvir sočasno uporablja.
In the first study, 16% of the Norvir-treated patients (86 out of 543) experienced a worsening of disease or died, compared with 33% of the patients taking placebo (181 out of 547).
V prvi študiji je do poslabšanja ali smrti prišlo pri 16% (86 od 543) bolnikov, ki so se zdravili z zdravilom Norvir, v primerjavi s 33% (181 od 547) bolnikov, ki so jemali placebo.
In the second study, patients taking Norvir had greater reductions in viral load and increases in CD4 cell counts than those taking zidovudine alone.
V drugi študiji so imeli bolniki, ki so prejemali zdravilo Norvir, večja znižanja virusnega bremena in povečanja števila celic CD4 kot tisti, ki so jemali le zidovudin.
The combination of Norvir and zidovudine was less effective than Norvir alone, although the reasons for this were unclear.
Kombinacija zdravil Norvir in zidovudin ni bila tako učinkovita kot zdravilo Norvir, uporabljeno samostojno, čeprav razlogi za to niso jasni.
Norvir, in combination with other antiviral medicines, could also reduce viral loads in children.
Zdravilo Norvir lahko v kombinaciji z drugimi protivirusnimi zdravili tudi pri otrocih zmanjša virusno obremenitev.
When it is used as a pharmacokinetic enhancer, the side effects of Norvir depend on the other antiviral medicine being taken.
Če bolnik zdravilo Norvir uporablja kot farmakokinetični stopnjevalec, so neželeni učinki odvisni od drugih protivirusnih zdravil, ki jih bolnik jemlje.
See the Package Leaflet provided with the other medicine for full details.
Za podrobne informacije glejte navodilo za uporabo, priloženo drugemu zdravilu.
When it is used as an antiviral medicine, the most common side effects with Norvir (seen in more than 1 patient in 10) are taste perversion (a bad taste in the mouth), circumoral and peripheral paraesthesia (abnormal sensations around the mouth, or in the hands or feet), headache, abdominal (tummy) pain, nausea (feeling sick), diarrhoea, vomiting and asthenia (weakness).
Če se zdravilo Norvir uporablja kot protivirusno zdravilo, so njegovi najpogostejši neželeni učinki (opaženi pri več kot 1 bolniku od 10) spremembe okusa (slab priokus v ustih), cirkumoralna in periferna parestezija (nenormalni občutki v predelu ust ali v rokah in nogah), glavobol, bolečine v trebuhu, slabost, diareja, bruhanje in astenija (šibkost).
For the full list of all side effects reported with Norvir, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Norvir, glejte navodilo za uporabo.
Norvir should not be used in people who may be hypersensitive (allergic) to ritonavir or any of the other ingredients.
Zdravila Norvir ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) ritonavir ali katero koli drugo sestavino zdravila.
It should not be used in patients who have severe problems with their liver.
Prav tako ga ne smejo uporabljati bolniki s hudimi težavami z jetri.
Norvir should not be used as an antiviral medicine by patients taking any of the following medicines: • alfuzosin (used to treat benign prostatic hyperplasia [BPH, enlarged prostate gland]); • meperidine, piroxicam, propoxyphene (used to relieve pain); • amiodarone, bepridil, encainide, flecainide, propafenone, quinidine (used to correct irregular heartbeat); • fusidic acid, voriconazole (at ritonavir doses of 400 mg twice a day or more), rifabutin (used to treat infections); • astemizole, terfenadine (commonly used to treat allergy symptoms - these medicines may be available without a prescription); • clozapine, pimozide (used to treat mental illness); • dihydroergotamine, ergonovine, ergotamine, methylergonovine (used to treat migraine headache); • cisapride (used to relieve certain stomach problems); • lovastatin, simvastatin (used to lower cholesterol in the blood); • clorazepate, diazepam, estazolam, flurazepam, midazolam (when taken by mouth), triazolam (used to relieve anxiety or difficulty sleeping); • St John’ s wort (a herbal preparation used to treat depression).
Zdravila Norvir kot protivirusnega zdravila ne bi smeli uporabljati bolniki, ki jemljejo katero koli izmed naštetih zdravil: • alfuzosin (uporablja se za zdravljenje benigne hiperplazije prostate [BPH, povečana prostata]); • meperidin, piroksikam, propoksifen (uporabljajo se za lajšanje bolečin); • amiodaron, bepridil, enkainid, flekainid, propafenon, kinidin (uporabljajo se za odpravljanje motenj srčnega ritma); • fusidna kislina, vorikonazol (ob odmerkih ritonavirja, ki znašajo vsaj 400 mg dvakrat na dan), rifabutin (uporablja se za zdravljenje okužb); • astemizol, terfenadin (navadno se uporabljata za zdravljenje simptomov alergije – ti zdravili utegneta biti na voljo brez recepta); • klozapin, pimozid (uporabljata se za duševne bolezni); • dihidroergotamin, ergonovin, ergotamin ali metilergonovin (uporabljajo se za zdravljenje migrenskih glavobolov); • cisaprid (uporablja se za lajšanje določenih težav z želodcem); • lovastatin, simvastatin (uporabljata se za znižanje holesterola v krvi);
Caution is also needed by patients taking Norvir at the same time as other medicines.
Previdnost je potrebna pri bolnikih, ki jemljejo zdravilo Norvir sočasno z drugimi zdravili.
See the Package Leaflet for full details.
Za celoten seznam omejitev glejte navodilo za uporabo.
2/ 3 As with other anti-HIV medicines, patients taking Norvir may be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).
Enako kot pri drugih zdravilih proti virusu HIV, lahko pride tudi pri bolnikih, ki jemljejo zdravilo Norvir, do lipodistrofije (sprememb v porazdelitvi telesnega maščevja), osteonekroze (odmiranja kostnega tkiva) ali sindroma imunske reaktivacije (simptomov okužbe, ki jih povzroči imunski sistem med okrevanjem).
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Norvir.
Bolniki, ki imajo težave z jetri (vključno z okužbo s hepatitisom B ali C) in prejemajo zdravilo Norvir, so izpostavljeni povišanemu tveganju za poškodbe jeter.
The Committee for Medicinal Products for Human Use (CHMP) decided that Norvir’ s benefits are greater than its risks in combination with other antiretroviral agents for the treatment of HIV-1 infected patients.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Norvir v kombinaciji z drugimi protiretrovirusnimi zdravili pri zdravljenju bolnikov, ki so okuženi s HIV- 1, večje od z njim povezanih tveganj.
The Committee recommended that Norvir be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Norvir odobri dovoljenje za promet.
Norvir was originally authorised under ‘ Exceptional Circumstances’, because, for scientific reasons, limited information was available at the time of approval.
Zdravilo Norvir je bilo prvotno odobreno „ v izjemnih okoliščinah “, ker podatki zaradi znanstvenih razlogov v času odobritve niso bili na razpolago.
As the company had supplied the additional information requested, the ‘ Exceptional Circumstances ’ ended on 13 March 2001.
Ko je družba predložila dodatne zahtevane podatke, so „ izjemne okoliščine “ dne 13. marca 2001 prenehale veljati.
Other information about Norvir:
Druge informacije o zdravilu Norvir:
The European Commission granted a marketing authorisation valid throughout the European Union for Norvir to Abbott Laboratories Limited on 26 August 1996.
Evropska komisija je dovoljenje za promet z zdravilom Norvir, veljavno po vsej Evropski uniji, odobrila družbi Abbott Laboratories Limited dne 26. avgusta 1996.
The marketing authorisation was renewed on 26 August 2001 and on 26 August 2006.
Dovoljenje za promet z zdravilom je bilo obnovljeno dne 26. avgusta 2001 in dne 26. avgusta 2006.
The full EPAR for Norvir can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Norvir je na voljo tukaj.
Norvir 80 mg/ ml oral solution
Norvir 80 mg/ ml peroralna raztopina
Alcohol (43% v/ v) Polyoxyl 35 Castor Oil Sunset Yellow (E110)
Alkohol (43% V/ V) Makrogolglicerol ricinolat 35 Oranžno barvilo FCF (E110)
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infected patients (adults and children of 2 years of age and older).
Ritonavir je indiciran za zdravljenje bolnikov (odraslih in otrok od 2. leta dalje), okuženih s HIV- 1, v kombinaciji z drugimi protiretrovirusnimi zdravili.
Adult use:
Uporaba pri odraslih: